How Much Do Peptides Cost? Real Monthly Prices and What Drives Them

This is the single biggest driver of the spread in the tier table below. A pharmacy compounding four peptides into one vial sources four bulk substances, verifies four certificates of analysis, weighs four quantities, and has to demonstrate that all four behave in the same solution. KLOW contains GHK-Cu, KPV, BPC-157 and TB-500; FORTIFY contains thymosin alpha-1, BPC-157, KPV and LL-37. Each is four procurement chains and four release problems, not one. Compare either against a single-molecule vial of BPC-157 on its own cost page and the gap is almost entirely ingredient count.

Two vials can hold the same volume and differ by orders of magnitude in how much active substance is dissolved in them. A repair peptide like BPC-157 is dosed in single-digit milligrams per vial. NAD+ Injection is dosed in a gram-scale load, because the molecule is used at a completely different weight. NAD+ is not an exotic or scarce substance — the vial costs more because there is simply far more substance in it. The same logic sets the gap between NAD+ Injection and its half-size sibling, NAD+ 500 mg.

Some peptides are straightforward solid-phase syntheses. Others carry a metal ion, a lipid tail, a disulfide bridge or a modification that has to be installed and then proven intact. A fifteen-amino-acid chain like BPC-157 is a different synthesis problem from a copper-bound tripeptide like GHK-Cu, where the copper has to be there in the right ratio and stay there, and both are different again from a molecule like semaglutide with a fatty-acid side chain engineered onto it. Difficulty of synthesis and difficulty of analysis both land in what a pharmacy pays per gram, before anyone has made a vial.

A multi-dose vial, a pre-filled Pen cartridge and a metered nasal bottle are three different processes with three different component costs and three different fill validations. Turning powder into any injectable is largely a fixed cost per batch rather than per milligram — reconstitute, filter through a sterilising membrane, fill under aseptic conditions, stopper, crimp, label, release against testing — which is why an inexpensive active ingredient does not produce an inexpensive vial. A metered nasal bottle is neither cheaper nor simpler: it holds substantially more solution than an injectable vial, and the pump is a component with its own specification. That is why Semax Nasal Spray, NAD+ Nasal and Selank Nasal sit on their own tier close to each other rather than tracking the prices of the injectable versions, and why the pepti Pen prices above the equivalent vial on every product that offers both.

For most peptides the vial is a fixed concentration and your directions determine how much of it you use. For GLP-1 medications the vial itself is compounded to your strength, so the cost of goods rises as you move up the ladder. That is a structural difference, not a pricing policy, and it is covered in its own section below.

Someone licensed in your state has to read your history, your medication list and your allergies, decide whether treatment is appropriate at all, write directions, and stay reachable afterwards for dose questions and side effects. Around that sits prescription transmission, pharmacy intake, state licensure checks, dispensing records, tracking, the re-review before each refill, and refrigerated overnight delivery with insulation and coolant. In an all-in model these are inside the published figure. In an unbundled model they are a membership, a consultation fee, a shipping charge and sometimes a refill fee. The medication can genuinely cost less in the second model and the patient can still pay more.

Semaglutide and tirzepatide are titrated. Treatment starts at a low weekly strength and moves up in steps over months, under the prescriber's direction, and where a patient settles is a clinical decision rather than a purchasing one. Because each fill is a vial compounded to the strength that patient is on, the pharmacy's cost of goods for a high rung is genuinely higher than for the starting rung. Pricing follows it.

The entry figure for a compounded GLP-1 is the first rung, not the average of a year. Anyone comparing a GLP-1 provider on the advertised starting number alone is comparing month one to month one, which is the least informative month. The comparison that matters is the price at the rung you are likely to be on for most of the year, and that is a question you should ask in writing before you start. Current per-strength pricing is published on semaglutide's cost page and tirzepatide's cost page.

A reasonable question, given that semaglutide and tirzepatide carry the deepest randomised human evidence in the catalog. Price does not track evidence; it tracks what the preparation costs to make and supply. A starting-rung GLP-1 vial holds a small milligram load of one molecule, which is structurally an inexpensive vial to fill.

At-home blood testing is priced separately, because most patients do not need it and pricing it into everyone's medication would be charging the majority for the minority. Where a physician requires labs before prescribing, that is a real additional cost and you should plan for it. At-home blood testing covers hormone, metabolic and thyroid markers without a lab visit, and the physician decides whether it is needed for you.

Insurance almost never reimburses any of this. The mechanics of why are in does insurance cover peptide therapy. The short version is that a compounded preparation does not carry the approval status and coding that a plan's formulary is built around.

HSA and FSA funds are frequently usable, which is the closest thing to a discount most patients will find. Rules vary by plan and some administrators want a letter of medical necessity, which your prescribing physician can discuss with you.

The FDA states it directly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." That applies to every compounded preparation regardless of price, provider or presentation, and it applies to the entire catalog on this site. No amount of money moves a compounded preparation into the approved category, and any provider implying otherwise is misdescribing what they sell. See are peptides FDA approved.

Compounded preparations are dispensed under section 503A of the Federal Food, Drug, and Cosmetic Act. The conditions are that the drug is compounded by a licensed pharmacist in a state-licensed pharmacy or by a physician, for an identified individual patient on a valid patient-specific prescription; that any bulk drug substance used has a USP monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list; and that the preparation is not essentially a copy of a commercially available drug product. Preparations meeting those conditions are exempt from premarket approval, from current good manufacturing practice requirements, and from the labelling requirement for adequate directions for use.

This is the most underappreciated line item in compounded pricing. A 503A preparation is made for you, against your prescription, and cannot be produced as anonymous inventory and sold off a shelf — which removes most of the batch economics that make a mass-manufactured product inexpensive per unit. Outsourcing facilities registered under section 503B may distribute without patient-specific prescriptions and are subject to CGMP and FDA inspection: a different regulatory bargain with a different cost structure.

Which substances a 503A pharmacy may compound is governed by the bulks list process. The FDA sorts nominated substances into three categories: Category 1, substances that may be eligible for the list and were nominated with sufficient supporting information, where the agency does not intend to take enforcement action if conditions are met; Category 2, substances for which the FDA has identified significant safety risks; and Category 3, substances nominated with insufficient information for the agency to evaluate.

As of the FDA's current listing, content current as of 22 April 2026, BPC-157 does not appear among the substances the agency identifies as presenting significant safety risks. That matters commercially as well as clinically: a substance's category determines whether a pharmacy will compound it at all, and availability is upstream of price. When a molecule becomes harder to source lawfully, its price does not fall.

Regulatory status sets what can be dispensed. It does not set the price, and it is not a quality grade you are buying up or down. The published figure buys a specific preparation made by a named, state-licensed pharmacy against a prescription from a physician licensed in your state. That is the whole of what the money purchases.

There is no published market survey of compounded peptide pricing, so anyone quoting an industry average is estimating. What can be stated plainly is what a given catalogue charges, which is why the prices on this page are the actual ones rather than a range invented for the article. They are also the reason this page links to /cost/ pages rather than repeating figures in prose: catalogue prices change, and a figure typed into a paragraph goes stale silently.

A higher price does not evidence a better preparation, and a lower one does not prove a worse one. What separates products is whether a licensed pharmacy compounded it against a prescription from a physician licensed in your state, and whether anyone is accountable for what is in the vial. Compounded medications are not FDA approved regardless of what they cost.

The molecules in the catalog with the deepest randomised human evidence are not the expensive ones. Semaglutide and tirzepatide have large randomised trials behind them in the New England Journal of Medicine, JAMA and the Lancet, and they sit at the bottom of the price table. Tesamorelin has a randomised trial in the New England Journal of Medicine in 2007 in patients with HIV-associated visceral fat accumulation, and CJC-1295 a 2006 study in the Journal of Clinical Endocrinology and Metabolism in healthy adults — both appear in blends near the top of the table. BPC-157, which has no large randomised human trials and rests on animal and cell research, sits in the middle. Price is set by what is in the vial and what it took to fill it, not by how much has been published about it. Judge the evidence separately, on each molecule's reference page.

The cheapest option by a wide margin, research-use-only vials, is cheap precisely because it removes the physician, the pharmacy and the recourse: see research peptides vs prescription peptides. No prescription means no clinician reviewed your medications. No named pharmacy means nobody is accountable for identity, purity, sterility or concentration. The saving is real and so is what it buys you out of.

For GLP-1 medications a rung change changes the price, because the vial is compounded to strength. For a fixed-concentration multi-dose vial like TB-500 or GHK-Cu, using more of the vial per dose does not change the monthly figure; if your physician moves you to a higher-strength vial, the price of that strength does.

Moving from a vial to a Pen cartridge, or from an injectable to a nasal spray, moves you to a different tier because it is a different preparation. Pen availability varies by product and is confirmed at checkout.

Two prescriptions are two preparations and two prices. It is worth asking your physician whether a blend covers what you were going to combine — a single vial containing four molecules generally prices below four separate vials, which is part of why KLOW, FORTIFY and REVIVE exist in the first place. Treatment here is long-term, on 28-day refills, and the subscription figure recurs while you are in treatment.